Stockscreener 앱 받기
1.20
4.00%
-0.05
시간 외 거래:
1.21
0.01
+0.83%
전일 마감가:
$1.25
열려 있는:
$1.28
하루 거래량:
99,621
Relative Volume:
0.74
시가총액:
$31.20M
수익:
$2,000
순이익/손실:
$-9.12M
주가수익비율:
-3.0825
EPS:
-0.3893
순현금흐름:
$-3.35M
1주 성능:
-11.11%
1개월 성능:
-11.11%
6개월 성능:
-44.19%
1년 성능:
-64.18%
1일 변동 폭
$1.20
$1.2823
1주일 범위
$1.19
$1.4152
52주 변동 폭
$0.8801
$3.60
Abvc Biopharma Inc Stock (ABVC) Company Profile
명칭
Abvc Biopharma Inc
전화
510-668-0881
주소
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
1.20 | 32.50M | 2,000 | -9.12M | -3.35M | -0.3893 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Abvc Biopharma Inc 주식(ABVC)의 최신 뉴스
MSN Money - MSN
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language - Stock Titan
Price to sales forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Enterprise value to EBITDA forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Price to book forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
ABVC Should I Buy - Intellectia AI
ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC) - TradingView
ABVC Q1 2025 Earnings: EPS of -0.06 Reflects Ongoing R&D Investment; Stock Gains 2.82%Earnings Yield Spread - dars.gov.et
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders - 富途牛牛
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Net Loss of $0.06 Per Share as Stock Rises 1.53% Amid No Reported RevenueForward Guidance Trends - dars.gov.et
ABVC BioPharma to Spin Off BioKey Subsidiary via Dividend Distribution to Shareholders - MEXC
ABVC Q1 2025 Earnings: Loss Per Share of -$0.06 as Clinical Pipeline ProgressesBook Value Growth - dars.gov.et
ABVC Biopharma Inc (ABVC) Institutional Confidence - TradingKey
ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressLow Estimate Range - dars.gov.et
ABVC Q1 2025 Earnings: No Revenue Reported, EPS Loss of -$0.06 Amid Ongoing R&D Focus - DonanımHaber
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC BioPharma Surges 6.64%: Shares Break Above Key Support as Momentum BuildsIchimoku Kumo Twist - dars.gov.et
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical DevelopmentReturn On Capital - dars.gov.et
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - The Legal Advocate
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - The Legal Advocate
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Surges 9.65% in Active Trading as Biotech Investor Sentiment ImprovesMcClellan Summation - The Legal Advocate
ABVC - Finviz
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
ABVC BioPharma Inc. (ABVC) Holds Near Support, Showing Cautious Recovery PotentialMedian Line - DonanımHaber
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline ProgressBuyback Announcement Report - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Holds Steady Above Support After Modest GainSocial Flow Trades - Newser
ABVC BioPharma Reports Continued Losses and No Revenue in Q1 2026, Raising Doubts About Financial Stability - Minichart
Why Is ABVC BioPharma, Inc. (ABVC) Stock Up Today? - Meyka
Why Is ABVC BioPharma, Inc. (ABVC) Stock Down Today? - Meyka
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary - TradingView
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit - TradingView
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning - Stock Titan
ABVC BioPharma Delays Quarterly SEC Filing - TipRanks
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026 - Stock Titan
Abvc Biopharma Inc (ABVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
3.77%
자본화:
|
볼륨(24시간):